Skye Bioscience, Inc. (SKYE)

Market Cap	46.77M
Revenue (ttm)	n/a
Net Income (ttm)	-26.57M
Shares Out	30.97M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	466,712
Open	1.550
Previous Close	1.570
Day's Range	1.450 - 1.630
52-Week Range	1.140 - 16.010
Beta	1.89
Analysts	Buy
Price Target	16.60 (+999.34%)
Earnings Date	May 9, 2025

About SKYE

Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company’s lead product candidate is nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, which is in Phase 2 clinical trial. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, I...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: SKYE
• Website: https://skyebioscience.com

Analyst Forecast

According to 6 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price forecast is $16.6, which is an increase of 999.34% from the latest price.

Price Target

$16.6

(999.34% upside)

Analyst Consensus: Buy